DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

1 API Suppliers, 1 Listed Suppliers

1 API Suppliers
1 Listed Suppliers

DEVELOPMENTS

4 Drugs in Development

4 Drugs in Development

DIGITAL CONTENT

9 NEWS #PharmaBuzz

media
9 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

4DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 944396-07-0, Nvp-bkm120, Bkm120, 5-(2,6-dimorpholinopyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-amine, Nvp-bkm-120, Bkm-120

Molecular Formula

C₁₈H₂₁F₃N₆O₂

Molecular Weight

410.4 g/mol

InChI Key

CWHUFRVAEUJCEF-UHFFFAOYSA-N

FDA UNII

0ZM2Z182GD

Buparlisib is an orally bioavailable specific oral inhibitor of the pan-class I phosphatidylinositol 3-kinase (PI3K) family of lipid kinases with potential antineoplastic activity. Buparlisib specifically inhibits class I PI3K in the PI3K/AKT kinase (or protein kinase B) signaling pathway in an ATP-competitive manner, thereby inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate and activation of the PI3K signaling pathway. This may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.

1 2D Structure

Buparlisib

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

5-(2,6-dimorpholin-4-ylpyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-amine

2.1.2 InChI

InChI=1S/C18H21F3N6O2/c19-18(20,21)13-9-15(22)23-11-12(13)14-10-16(26-1-5-28-6-2-26)25-17(24-14)27-3-7-29-8-4-27/h9-11H,1-8H2,(H2,22,23)

2.1.3 InChI Key

CWHUFRVAEUJCEF-UHFFFAOYSA-N

2.1.4 Canonical SMILES

C1COCCN1C2=NC(=NC(=C2)C3=CN=C(C=C3C(F)(F)F)N)N4CCOCC4

2.2 Other Identifiers

2.2.1 UNII

0ZM2Z182GD

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Bkm120

2. Nvp-bkm120

2.3.2 Depositor-Supplied Synonyms

1. 944396-07-0

2. Nvp-bkm120

3. Bkm120

4. 5-(2,6-dimorpholinopyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-amine

5. Nvp-bkm-120

6. Bkm-120

7. 1202777-78-3

8. Bkm 120

9. Buparlisib (bkm120)

10. Nvp-bkm 120

11. Bkm120 (nvp-bkm120, Buparlisib)

12. 5-(2,6-dimorpholin-4-ylpyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-amine

13. Bkm-120nx

14. Bkm120-nx

15. 5-[2,6-di(morpholin-4-yl)pyrimidin-4-yl]-4-(trifluoromethyl)pyridin-2-amine

16. 0zm2z182gd

17. Chembl2017974

18. Chebi:71954

19. 944396-07-0 (free Base)

20. 2-pyridinamine,5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-(trifluoromethyl)-

21. 5-[2,6-di(4-morpholinyl)-4-pyrimidinyl]-4-(trifluoromethyl)-2-pyridinamine.

22. Buparlisib [inn]

23. Buparlisib [usan:inn]

24. Unii-0zm2z182gd

25. Bkm 120nx

26. 5-[2,6-di(4-morpholinyl)-4-pyrimidinyl]-4-(trifluoromethyl)-2-pyridinamine

27. Sd5

28. Buparlisib; Bkm120

29. 3sd5

30. Buparlisib (usan/inn)

31. Buparlisib [usan]

32. Buparlisib [who-dd]

33. Mls006010984

34. Schembl146956

35. Gtpl7878

36. Bkm120,nvp-bkm120

37. Ammd00049

38. Bkm-120 (pi3k)

39. Dtxsid50241486

40. Ex-a189

41. Hms3295i15

42. Hms3655d16

43. Bkm120 (nvp-bkm120)

44. Bkm120 - Nvp-bkm120

45. Bdbm50380363

46. Mfcd18251596

47. Nsc754353

48. Nsc799370

49. S2247

50. Zinc43154039

51. 2-pyridinamine, 5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-(trifluoromethyl)-

52. 5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-(trifluoromethyl)-2-pyridinamine

53. Akos016005372

54. Am85983

55. Bcp9001011

56. Ccg-264954

57. Cs-0089

58. Db11666

59. Nsc-754353

60. Nsc-799370

61. Sb16577

62. Ncgc00262604-01

63. Ncgc00262604-08

64. Ac-32077

65. Ac-35575

66. As-40568

67. Hy-70063

68. Smr004702786

69. Db-079882

70. Ft-0755923

71. Sw218149-2

72. A25436

73. D10584

74. A892274

75. J-516601

76. Brd-k42191735-001-01-2

77. Q25100534

78. 4-(trifluoromethyl)-5-(2,6-dimorpholinopyrimidin-4-yl)pyridin-2-amine

79. 5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine

80. 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine

2.4 Create Date

2007-08-09

3 Chemical and Physical Properties

Molecular Formula	C₁₈H₂₁F₃N₆O₂
Molecular Weight	410.4 g/mol
XLogP3	1.5
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	11
Rotatable Bond Count	3
Exact Mass	410.16780842 g/mol
Monoisotopic Mass	410.16780842 g/mol
Topological Polar Surface Area	89.6 Å²
Heavy Atom Count	29
Formal Charge	0
Complexity	530
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1